Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 19:14:47-74.
doi: 10.2147/DNND.S452009. eCollection 2024.

Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management Using Traditional Medicinal Plants

Affiliations
Review

Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management Using Traditional Medicinal Plants

Prabhash Nath Tripathi et al. Degener Neurol Neuromuscul Dis. .

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. While there is currently no cure for AD, several pharmacotherapeutic targets and management strategies have been explored. Additionally, traditional medicinal plants have gained attention for their potential role in AD management. Pharmacotherapeutic targets in AD include amyloid-beta (Aβ) aggregation, tau protein hyperphosphorylation, neuroinflammation, oxidative stress, and cholinergic dysfunction. Traditional medicinal plants, such as Ginkgo biloba, Huperzia serrata, Curcuma longa (turmeric), and Panax ginseng, have demonstrated the ability to modulate these targets through their bioactive compounds. Ginkgo biloba, for instance, contains flavonoids and terpenoids that exhibit neuroprotective effects by reducing Aβ deposition and enhancing cerebral blood flow. Huperzia serrata, a natural source of huperzine A, has acetylcholinesterase-inhibiting properties, thus improving cholinergic function. Curcuma longa, enriched with curcumin, exhibits anti-inflammatory and antioxidant effects, potentially mitigating neuroinflammation and oxidative stress. Panax ginseng's ginsenosides have shown neuroprotective and anti-amyloidogenic properties. The investigation of traditional medicinal plants as a complementary approach to AD management offers several advantages, including a lower risk of adverse effects and potential multi-target interactions. Furthermore, the cultural knowledge and utilization of these plants provide a rich source of information for the development of new therapies. However, further research is necessary to elucidate the precise mechanisms of action, standardize preparations, and assess the safety and efficacy of these natural remedies. Integrating traditional medicinal-plant-based therapies with modern pharmacotherapies may hold the key to a more comprehensive and effective approach to AD treatment. This review aims to explore the pharmacotherapeutic targets in AD and assess the potential of traditional medicinal plants in its management.

Keywords: Alzheimer’s disease; Ayurvedic herbs; acetylcholinesterase; acetylcholinesterase inhibitors; amyloid beta; cognition; neurodegenerative disorders; tau protein; traditional medicine.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Biosynthesis of acetylcholine and cholinergic transmission.
Figure 2
Figure 2
α-, β-, and γ-secretase pathway.
Figure 3
Figure 3
Tau hypothesis cascade.
Figure 4
Figure 4
Chemical structures of FDA-approved drugs for the treatment of AD.
Figure 5
Figure 5
Ayurveda’s approaches to treating AD.
Figure 6
Figure 6
Phytoconstituents of Ayurvedic medicinal plants used for AD.

References

    1. Toodayan N. Professor Alois Alzheimer (1864–1915): lest we forget. J Clin Neurosci. 2016;31:47–55. doi: 10.1016/j.jocn.2015.12.032 - DOI - PubMed
    1. Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Front Aging Neurosci. 2022;14:937486. doi: 10.3389/fnagi.2022.937486 - DOI - PMC - PubMed
    1. Thébaut C, Achille D, Preux P, Guerchet M. Costs of Dementia in Low-And Middle-Income Countries: a Systematic Review. J Alzh Dis. 2022;2022:1. - PubMed
    1. Huo Z. The Disease Burden and Economic Cost of Dementia in an Asian Population. Hong Kong: The Chinese University of Hong Kong; 2021.
    1. Elfaki BA. Factors contributes to overweight and obesity among young adults; 2023.